Serum levels of interleukin 33 and its receptor ST2 in patients treated with subcutaneous allergen immunotherapy in intermittent allergic rhinitis
Serum levels of interleukin 33 and its receptor ST2 in patients treated with subcutaneous allergen immunotherapy in intermittent allergic rhinitis
复制标题
DOI：
10.5114/ceji.2019.87075
复制
发表时间：
2019-01-01
影响因子：
1.3
通讯作者：
Rogala, Barbara
中科院分区：
文献类型：
--
作者：
Gluck, Joanna;Rymarczyk, Barbara;Rogala, Barbara
白细胞介素33（IL-33）是一种多效性细胞因子，参与季节性变应性鼻炎的病理过程。IL-33与ST 2受体结合，ST 2受体在肥大细胞上高度表达，并选择性地在Th 2细胞上表达。信息是缺乏对过敏原皮下immunotherapy.Aim的作用IL-33/ST 2轴的研究：为了确定是否过敏原免疫治疗改变IL-33/ST 21轴在季节性变应性鼻炎patients.Material和方法：40例间歇性变应性鼻炎敏感的草和/或树花粉进行了研究。其中，10例患者在完成第一个免疫治疗疗程后的随访中进行了纵向评估。22名健康受试者作为对照。根据包括建立和维持阶段的常年时间表应用免疫疗法。结果：IL-33兰德在第1疗程免疫治疗后明显升高，并达到对照组水平。血清水平的ST 2可比前的花粉季节和免疫治疗的第一个疗程后：IL-33的血清水平的增加后，第一个疗程的免疫治疗可能表明，这是太短的时间，以防止预期的提高血清IL-33水平在花粉季节，和更长的治疗需要观察到显着的变化，这种细胞因子。ST 2血清水平与免疫治疗和花粉季节无关。
Introduction: Interleukin 33 (IL-33) is a pleiotropic cytokine involved in pathological processes in seasonal allergic rhinitis. IL-33 binds to ST2 receptor, which is highly expressed on mast cells and selectively on Th2 cells. Information is lacking on the role of IL-33/ST2 axis in allergen subcutaneous immunotherapy.Aim of the study: To determine if allergen immunotherapy changes the IL-33/ST2l axis in seasonal allergic rhinitis patients.Material and methods: 40 patients with intermittent allergic rhinitis sensitive to grass and/or tree pollen were studied. Among these, 10 patients were longitudinally assessed in the follow-up visit after completing the first course of immunotherapy. Twenty-two healthy subjects were included as controls. Immunotherapy was applied according to a perennial schedule comprising up-building and maintenance phases. Serum levels of ST2/IL-33 Rand IL-33 were measured by ELISA (R&D Systems).Results: Serum levels of IL-33 significantly rose after the first course of immunotherapy and reached the controls levels. Serum levels of ST2 were comparable before the pollen season and after the first course of immunotherapy.Conclusions: Increase in serum levels of IL-33 after the first course of immunotherapy may suggest it is too short period to prevent the expected raise in serum IL-33 levels in the pollen season, and longer treatment is required to observe significant changes of this cytokine. ST2 serum levels are independent of immunotherapy and pollen season.